for people ages 18 years and up (full criteria)
at La Jolla, California and other locations
study started
completion around



ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC).

Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis.

The goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance.

Official Title

Exoluminate Study: Observational Registry Study to Assess Exo-PDAC Assay Performance for Detection of Pancreatic Adenocarcinoma (PDAC) in High-Risk or Clinically Suspicious Patients


Biological Dynamics, Inc. has developed a non-invasive blood test ("liquid biopsy") that can identify early-stage disease with high sensitivity and specificity. The proprietary ExoVerita™ assay uses alternating current electric (ACE) field to isolate extracellular vesicles (EVs) for differentiated multiomics applications and includes an optimized machine learning algorithm to identify a panel of EV-bound protein biomarkers in patient's plasma in order to detect PDAC at earlier stages.

ExoLuminate is a prospective, multi-center, observational registry study designed to evaluate the non-inferiority of the performance of the ExoVerita™ assay in detecting pancreatic ductal adenocarcinoma (PDAC) in high-risk or clinically-suspicious populations in comparison to standard-of-care methods.

The study is planned to recruit a minimum of 1000 U.S. adults over 3-years (with a 2-year follow-up for data collection).

Eligible subjects will be evaluated using the ExoVerita™ assay through blood donation(s) at specified time intervals. Overall, this study poses minimal risk to subject.


Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms, Early Detection, IPMN, PDAC, Pancreatic Cancer, Personal history of PDAC, Pancreatic cysts


You can join if…

Open to people ages 18 years and up

  • ≥18 years old.
  • Meeting criteria for one of the study cohorts.
  • Capable of giving informed consent.
  • Able to provide a blood sample.

You CAN'T join if...

  • < 18 years old.
  • Pregnancy.
  • Active cancer (other than pancreatic cancer) and/or undergoing treatment for an active cancer diagnosis (except for skin malignancies).
  • Prior organ transplant or bone marrow transplant.
  • History of fainting or other adverse effects when blood is drawn.
  • Any condition that, in the opinion of the investigator, should preclude enrollment.


  • University of California, San Diego accepting new patients
    La Jolla California 92093 United States
  • Biological Dynamics accepting new patients
    San Diego California 92121 United States


accepting new patients
Start Date
Completion Date
Biological Dynamics
Biological Dynamics, Inc. Website ExoLuminate Study Website for Providers
Study Type
Observational [Patient Registry]
Expecting 1000 study participants
Last Updated